Pinned Tweet
Had the opportunity to talk about heart failure on @FirstCoastNews
Raising awareness is crucial to improving care and outcomes. #heartfailure
#Cardiology
#HealthAwareness
firstcoastnews.com/video/ent…
Sharon Natanzon retweeted
Flail P2 with torrential MR, treated with M-TEER and reduced to trace-mild MR using two devices (MitraClip XTW and XT).
A striking before-and-after comparison.
#StructuralHeart #CardioTwitter @alizgheib @ufjaxcards
Sharon Natanzon retweeted
Multivalvular disease is challenging and remains an evidence gap. This CMR-powered study helps clarify the natural history of moderate AS with concomitant MR—a dual-valve phenotype with worse remodeling and outcomes than isolated severe AS. @JACCJournals #WhyCMR
Sharon Natanzon retweeted
🚨🫀 Cardiac CT is no longer just about coronary stenosis.
Photon-Counting CT is turning it into full cardiac phenotyping.
And that changes everything.
A new JACC editorial makes it clear:
👉 We are moving from coronary angiography
to
👉 comprehensive myocardial + coronary characterization in one scan
This is not an upgrade.
This is a paradigm shift.
What PCCT can now do:
✔ Coronary stenosis assessment
✔ Plaque characterization
✔ LV mass + function
✔ Extracellular volume (ECV)
✔ Late iodine enhancement (LIE) for fibrosis detection
✔ Myocardial tissue characterization
👉 All in a single examination
And the numbers are impressive:
Compared with CMR:
📊 LV mass index → r = 0.963
📊 Ejection fraction → r = 0.947
📊 ECV → r = 0.868
📊 LIE vs LGE → 99–100% segment concordance
📊 Diagnostic accuracy → AUC 0.994
📊 Sensitivity 99% | Specificity 100%
Let that sink in.
The real implication?
We stop asking only:
❌ “Is there obstructive CAD?”
And start asking:
✅ What is the plaque biology?
✅ Is there fibrosis?
✅ Is this hypertrophy, amyloid, HCM, or infiltration?
✅ What is the full cardiac phenotype?
My take:
This perfectly supports what many still underestimate:
PCCT is not better coronary CTA.
It is the beginning of a new cardiovascular imaging modality.
From anatomy
➡️ to biology
From stenosis
➡️ to disease
From isolated findings
➡️ to integrated phenotyping
⚡ The future of cardiac imaging is not another test.
👉 It’s one scan that answers the real question:
What is happening to this patient’s heart?
Sharon Natanzon retweeted
Welcome to another @MonteHeart Imaging and Clinical Lecture
Friday, March 6, 2026. From 12:00 pm EST – 1:00 pm EST @salernomdphd
Link: einsteinmed.zoom.us/j/941700…
Sharon Natanzon retweeted
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension: @CircAHA
🥸 Many patients have higher wedge + type 1 PulmHTN - this reports describes this group in detail.
😱 Take a look below:
👇👇👇👇
Sharon Natanzon retweeted
Acute eosinophilic myocarditis may present without peripheral eosinophilia in up to 57.4% of cases - making endomyocardial biopsy essential, as reliance on blood eosinophils risks missed diagnosis.ahajrnls.org/3Zii2BM
Sharon Natanzon retweeted
Machine learning-based phenotyping and assessment of treatment responses in heart failure with preserved ejection fraction
Machine learning-based algorithm identifies HFpEF phenogroups with distinct clinical features and treatment responses. This study suggests that SGLT2i and ARNI have a role in improving the outcomes in patients with metabolic comorbidities and both systolic and diastolic impairment, while calcium channel blockers were most likely to benefit HFpEF patients with atrial fibrillation
#Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare
@hfcollaboratory @CircHF @TheLancet @mvaduganathan @hvanspall @BiykemB @AndrewJSauer @ankeetbhatt
thelancet.com/journals/eclin…
Highly recommended conference
Just over a month left to register for our January 2026 three-day conference at Cedars-Sinai, “Advances in Nuclear Cardiology, Cardiac CT, and Cardiac MRI,” with some of the most well-known speakers in the field. View the course agenda and register at cedars.cloud-cme.com/nuclear…
2
191
Sharon Natanzon retweeted
Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance
CMR with ECV mapping can track changes in cardiac amyloid burden and treatment response in ATTR-CM, with changes in ECV being independently associated with outcomes.
#Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare
@CMichaelGibson @DrMarthaGulati @hvanspall @Hragy @iamritu @AndrewJSauer @ankeetbhatt @biljana_parapid @AnastasiaSMihai @MasriAhmadMD
academic.oup.com/eurheartj/a…
Sharon Natanzon retweeted
Stellar @SmidtHeart faculty-driven program, featuring the best of the best! Strongly recommended for anyone interested in cardiac imaging.
Just over a month left to register for our January 2026 three-day conference at Cedars-Sinai, “Advances in Nuclear Cardiology, Cardiac CT, and Cardiac MRI,” with some of the most well-known speakers in the field. View the course agenda and register at cedars.cloud-cme.com/nuclear…
Sharon Natanzon retweeted
The Ultimate CPET Thread
How to Decode Dyspnea Using Physiology (Braunwald + Clinical Insights)
CPET is not just a stress test, It is a complete physiologic study of the heart, lungs, and muscles working together under stress
A 🧵
Proud of our cardiology fellows and internal medicine residents.
@UFMedicineJax @ufjaxcards
ahajournals.org/doi/10.1161/…
1
2
93
Sharon Natanzon retweeted
SGLT2i & UTI: Continue or Stop?
🧩 Key Question:
What happens when patients with T2DM on SGLT2 inhibitors develop a new-onset UTI?
Should therapy be continued or discontinued thereafter?
🔍 Key Finding (EHJ, 2025 | doi:10.1093/eurheartj/ehaf788)
In >61,000 T2DM patients on SGLT2i (2015–2022):
🔹 6.3% developed a new-onset UTI during follow-up.
🔹 Those with UTI had markedly higher risks of:
🫀 CV composite events (HR 3.18; 95% CI 2.88–3.51)
💧 Renal composite events (HR 2.51; 95% CI 2.32–2.72)
After UTI, 32% stopped SGLT2i.
🚫 Discontinuation increased:
🫀 CV risk → HR 1.35 (1.20–1.53)
💧 Renal risk → HR 1.35 (1.21–1.51)
💊 No significant reduction in recurrent UTI risk (HR 0.96).
💡 Take-Home Message
🌊 New-onset UTI is a marker of vulnerability — signalling higher cardio-renal risk.
❌ Stopping SGLT2 inhibitors post-UTI worsens CV and renal outcomes, without lowering reinfection risk.
✅ Best approach:
– Treat UTI appropriately 🔬
– Resume or continue SGLT2 inhibitor once infection resolves
– Maintain long-term CV-renal protection 🌿
🩺 Clinical Insight
“UTI is a complication; discontinuation is a setback.”
Keep the molecule — protect the heart & kidney, not just the bladder. 💚
Source:
📘 European Heart Journal (2025): Wu M-Z et al., Urinary tract infection and continuation of sodium–glucose cotransporter-2 inhibitors in diabetic patients.
🔗
academic.oup.com/eurheartj/a…
Sharon Natanzon retweeted
Multimodality imaging in advanced #HeartFailure (part 2):
#HFA_ESC Clinical Consensus Statement on #MCS & #HeartTransplantation 🫀
In #advancedHF care, #CVimaging is not just diagnostic, it is longitudinal surveillance across #LVAD and post-transplant care:
📍Candidate selection, ventricular+valve function, device positioning, unloading assessment, evaluation of #RV failure & device complications
📍Graft function, perfusion & rejection evaluation, CAV monitoring
More🔗: doi.org/10.1002/ejhf.70018
@escardio @EJHFEiC @ESC_Journals
@MarcoMetra @jozinetm @AlbertoAimo90 @MajaCikes @FinnGustafsson @kevin_damman @juliendreyfus1
#EchoFirst #yesCCT #whyCMR #ThinkPET
Sharon Natanzon retweeted
In symptomatic #nHCM, #mavacamten improved LV diastolic & LA function with modest LVH regression, but 1 in 5 demonstrated an #LVEF <50%, which reversed following therapy interruption. jacc.org/doi/10.1016/j.jacc.…
#JACC #ESCCongress #WCCardio @DesaiMilindY
Sharon Natanzon retweeted
Treatment with #mavacamten for 48 weeks in #nHCM patients was associated with marked biomarker improvements compared with placebo. Long-term effects on remodeling, health status, and outcomes remain uncertain. jacc.org/doi/10.1016/j.jacc.…
#JACC #ESCCongress #WCCardio @DesaiMilindY
Fantastic representation of the @UFMedicineJax heart failure team in Heart Failure Management 2025.
1
5
179
Sharon Natanzon retweeted
🆕💥📸 Cardiac CT 🍩for Prosthetic Heart Valve Assessment ☮️: Multi-societal Expert Consensus 👉🏼jacc.org/doi/10.1016/j.jacc.… #SCCT #ACC @RSNA @ACCinTouch @SCAI #NASCI #ESCR
Honored to be nominated for teacher of the year award.
@ufjaxcards @UFMedicineJax
Sharon Natanzon retweeted
Currently in #JACCHF: FUTURE-HF, the first-in-human study of an implantable IVC sensor for remote HF monitoring, was found to be safe & feasible, with improvements in #NTproBNP, NYHA class, #QoL, & reduced #heartfailure events.
More: jacc.org/doi/10.1016/j.jchf.… @kevin_damman @umcg













































